InnoCare, a leading innovator for global biopharmaceutical drugs, is proud to announce the appointment of Shaojing Tong as Chief Financial Officer (CFO). Mr. Tong has been a leading healthcare research analyst for the Asia-market and has extensive knowledge of the industry. Reporting directly to the CEO, Dr. Jasmine Cui, Mr. Tong will be responsible for the financial strategy development, risk management, and investment analysis.
Mr. Tong is considered one of Hong Kong’s top research analysts for the entire biopharmaceutical and healthcare sector, repeatedly being ranked in the “Best Analyst Team” of the Asian healthcare industry. Mr. Tong has many years of experience in managing investment analyst teams and has acquired comprehensive knowledge of the industries history, value chains, and developmental trends. Before joining InnoCare, Mr. Tong served as an executive director and industry analyst at UBS China, where he covered medical companies for both the Hong Kong and A-class China markets. Prior to UBS, Mr. Tong was a healthcare research analyst for Bank of America Merrill Lunch (Hong Kong) and Michael Partners (New York). Preceding his financial career, Mr. Tong worked in drug development for CADUS Pharmaceuticals (New York).
Mr. Tong received a Bachelor of Science degree in materials science and engineering from the University of Science and Technology of China. He obtained a Master’s degree in chemistry at the University of Pittsburg, and a Master of Business Administration (MBA) from New York University.
“We are very pleased to have Mr. Tong onboard,” said Dr. Cui, CEO and Chairman of InnoCare, “His extensive knowledge and unique insight of the biopharmaceutical industry will help cement a strong financial foundation for InnoCare so that we can continuously build towards our goal of becoming a global leader for innovative drugs.”
“I am honored to be a member of InnoCare and work with such an outstanding team,” Mr. Tong said, “InnoCare is a leader among Chinese innovative pharmaceutical companies, establishing a wealth of product pipeline in a very short amount of time. I look forward to joining such an experienced and passionate team, and will advance InnoCare’s goal of providing safe, effective, and affordable drugs for patients around the world.”